Kornimate/medical-research-clean huggingface dataset:
the association between very small embryonic-like stem cells and the prognosis of coronary artery disease patients

Conditions: Coronary Artery Disease

Summary: hypothesis: peripheral blood very small embryonic-like stem cells (vsels) are different in coronary artery disease (cad) patients from those without cad, which might account for the benefits of atorvastatin in cad patients.

1. hypothesis: the vsels might be mobilized in the situation of cardiac ischemia in cad patients. in addition, the benefits derived from atorvastatin administration in cad patients may be related to vsels via scd40l-sdf1/cxcr4 signal pathway. 2. the number and function of peripheral blood vsels in cad patients compared with the controls. 1. included patients: including 200 cad patients receiving coronary angiography (cag) as positive subjects, 100 as control who are negative for cag. 2. the irb approve and all subjects sign the informed consent. 3. all subjects will receive the detection and analysis of the peripheral blood vsels, including vsel number, immigration capability after scd40l administration. 4. all subjects will receive the follow-up for 1 year, and the mace (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death. 5. the association between vsels and mace in cad patients will be statistically analyzed. 3. atorvastatin administration improves the prognosis of cad patients through exerting impacts on vsels 1. included patients: including 200 cad patients receiving coronary angiography as positive subjects, 100 as control who are negative for coronary angiography. 2. the irb approve and all subjects sign the informed consent. 3. fifty cad subjects will receive intensive atorvastatin administration and 50 cad patients receiving the routine atorvastatin administration as controls. 4. all subject will receive the follow-up for 1 year, and peripheral blood vsels, sdf-1/cxcr4 are tested, and the mace (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death. 5. the intensive atorvastatin protocol indicates that 80mg atorvastatin will be administrated before cag, and then are followed with 20mg atorvastatin during the entire study period. 6. the routine atorvastatin protocol indicates that 20mg atorvastatin daily during the entire study period.

Eligibility criteria:
inclusion criteria: * cad patients receiving coronary angiography (cag) as positive subjects, 100 as control who are negative for cag. exclusion criteria: * infectious diseases, immunologically mediated disease, serious liver diseases, serious kidney diseases, malignant tumor, thrombocytopenia, pregnancy, occluded peripheral arterial diseases, bleeding or blood transfusion in the latest 2 months
the value of immunohistochemical expression of moesin in endometrial hyperplasia and endometrial carcinoma

Conditions: Endometrial Cancer and Endometrial Hyperplasia

Summary: endometrial carcinoma (ec) is the most prevalent invasive carcinoma of the female genital tract in developed countries, while it ranks as the second most frequently occurring neoplasm of women in developing countries, after carcinoma of the cervix uteri. the vast majority of ecs occur in perimenopausal and postmenopausal women . ecs are classified into two distinct phenotypes; type i which represents more than 80% of all cases of ecs, it has a favorable prognosis. this type is linked to excess, unopposed hyper-estrogenic condition and it is almost always preceded by endometrial hyperplasia. on the contrary, type ii endometrial carcinoma is less common than type i, representing less than 10% of all cases of ecs. type ii endometrial carcinomas are high grade, poorly differentiated and estrogen-independent tumors .


Eligibility criteria:
inclusion criteria: * hysterectomy specimens diagnosed as endometrial hyperplasia and endometrial adenocarcinoma. * all cases of endometrial biopsies obtained by curettage (d\&c) diagnosed as endometrial hyperplasia. * cases of cyclical endometrium obtained from endometrial curettage or hysterectomy specimens done for pathological conditions other than hyperplastic or neoplastic endometrial lesions. * complete clinical data. exclusion criteria: * patients with a history of preoperative chemotherapy and /or radiotherapy. * biopsies with predominantly blood clots. * insufficient or tiny tissue biopsies.
efficacy of ex-situ normothermic perfusion versus cold storage in the transplant with steatotic liver graft.

Conditions: Liver Transplant

Summary: prospective, randomized, controlled clinical trial to determine the overall efficacy of normothermic machine perfusion (nmp) for steatotic liver preservation versus traditional static cold storage (scs), in 50 liver transplant recipients with 1-year follow-up.

this is a prospective, randomized, controlled clinical trial comparing static cold storage (scs) versus normothermic machine perfusion (nmp) for organ preservation before liver transplantation with steatotic livers (between 30 % and 60% of histologic macrovesicular steatosis), in order to: main objective: to compare the effect of nmp versus scs in preventing preservation injury and graft dysfunction, as measured by highest transaminase levels during the first week after liver transplantation. secondary objectives: * to compare graft and patient survival between the nmp and scs steatotic livers. * to compare the liver biochemical function between the nmp and scs steatotic livers. * to compare the physiological response to the reperfusion between the nmp and scs steatotic livers. * to compare the evidence of reperfusion injury between the nmp and scs steatotic livers. * to compare the evidence of ischemic cholangiopathy between the nmp and scs steatotic livers.

Eligibility criteria:
inclusion criteria: liver donor: * donors older than 16 years * liver donation grafts due to brain death * steatosis confirmed by histological study (between 30% and 60% of macrovesicular steatosis) liver recipient: * adult patients (18 years or older) * active liver transplant waiting list candidate * able to give informed consent exclusion criteria: liver donor: * living donors * liver destined to the transplant "split" * donor age \<16 years * donation after death due to asystole. * when the biopsy establishes a steatosis ≥ 50%, patients who fulfill at least 3 of the following 5 risk factors will be excluded: transaminases (ast and alt) ≥ 200 u / l; age ≥ 55 years; hypernatremia ≥ 155 meq / l; cardiovascular risk factors, at least 2 of the following 5: dm, hta, imc ≥ 35, active smoking, ischemic stroke; days of stay in icu ≥ 4 days with vasoactive drugs (noradrenaline or dobutamine at any dose) liver recipient: * age under 18 * acute/fulminant hepatic failure * transplant of more than one organ (for example, liver and kidney) * rejection of informed consent * unable to give informed consent
prasugrel with lower dose - loading dose

Conditions: Coronary Artery Disease

Summary: although prasugrel, recently available thienopyridine derivative, exhibits rapid and potent platelet inhibition, concerns of low on-treatment platelet reactivity have been suggested especially in east asian ethnicities. the investigators compared the effect of lower loading dose of prasugrel with conventional loading dose of clopidogrel and prasugrel.

although clopidogrel together aspirin has been a backbone of anti-platelet therapy in coronary artery disease patients, clopidogrel has several limitations. it has delayed onset of peak concentration and pharmacodynamic inter-patient response variability resulting in high on-treatment platelet reactivity (hpr). those demerits are known to be associated with adverse cardiovascular outcomes. prasugrel has a more effective metabolism pathway than clopidogrel and exhibits more rapid and potent platelet inhibition. recent guidelines recommend prasugrel as a first line antiplatelet agent or put precedence over clopidogrel for the patients with acute coronary syndrome. however, there have been concerns of different pharmacodynamic and pharmacokinetic response to prasugrel in east asian ethnicities. in addition, lower loading dose of prasugrel exhibited more potent pharmacodynamic effect than clopidogrel 600 mg with comparable efficacy compared to conventional loading dose of prasugrel in healthy korean subjects. the investigators compare the antiplatelet effect of lower loading dose of prasugrel 30 mg with conventional loading dose of clopidogrel 600 mg and prasugrel 60 mg in korean coronary artery disease patients undergoing elective coronary angiography.

Eligibility criteria:
inclusion criteria: * patients between 18 and 80 years * stable or unstable angina * planned to undergo elective coronary angiography exclusion criteria: * previous history of transient ischemic attack or stroke * intracranial neoplasm * uncontrolled malignant disease * history of antiplatelet or anticoagulation treatment within 1 month * contraindication to the study drug * bleeding diathesis * hemoglobin \< 10 g/dl * platelet count \< 100,000/mm3 * significant renal insufficiency (glomerular filtration rate \<60 ml/min/1.73 m2) * significant hepatic impairment (serum liver enzyme or bilirubin \> 3 times normal limit) * body weight \< 50 kg

Keywords: coronary artery disease prasugrel platelet function tests
thrive apneic ventilation with standardized airway management during general anesthesia.

Conditions: Apnea; Ventilation Therapy; Complications; Respiratory Acidosis

Summary: transnasal humidified rapid-insufflation ventilatory exchange (thrive) denotes the use of high-flow humidified nasal oxygen system (for example optiflow®) as an alternative ventilation modality for an anesthetized patient without spontaneous respiration. this method requires only basic airway management manoeuvres to keep the airway open and provides both stable longterm oxygenation as well as apneic ventialtion. we plan to evaluate this methods physiological performance under standardized conditions of airway management by frequent, repeated arterial blood gas analyses.

thrive is previously shown feasible as sole mode of ventilation in selected patients during general anaesthesia for minor laryngeal surgery for a limited time up to 30 minutes, where direct laryngoscopy was required and applied throughout the procedure. a stable oxygenation and a degree of ventilation was observed. however, a slowly developed respiratory acidosis was also observed over time. existing physiologic studies on high flow humidified nasal oxygen suggest that closed mouth breathing enhance the effects of the high flows of oxygen levels applied by increasing the airway pressures and thereby enhance gas exchange in the lungs. currently, it is unclear whether the efficiency of thrive depends on the particular circumstances of airway management. physiologic characterization of thrive performance under standardized conditions of airway management and under close monitoring by systematic analysis of blood gas dynamics over time during general anesthesia is needed. we plan to study the blood gas dynamics during thrive apnea ventilation during general anesthesia, where the airway is managed only by jaw-thrust for up to 60 minutes. the patients will be closely monitored by repetitive arterial blood gasses to evaluate blood gas dynamics and development of respiratory acidosis. desaturation or respiratory acidosis with ph under 7.15 and/or paco2-rise \> 12 kpa will lead to cessation of thrive.

Eligibility criteria:
inclusion criteria: 1. adult (age over 18 years) 2. elective surgery where intubation is not mandatory 3. the patient can understand the information about the study and give their informed written consent of participation exclusion criteria: 1. asa (american society of anaesthesiologists class) \> 3 2. nyha (new york heart association class) \> 2 3. bmi \> 30 kg/m2 4. symptomatic respiratory disease 5. symptomatic cardiac disease 6. evidence of arteriosclerotic disease 7. neuromuscular disease 8. pregnancy 9. presumed or predicted difficult airway (sari - simplified airway risk index score \> 4) 10. known or suspected nasal congestion/stenosis or catharalia
epidemiology of bunion and risk factors

Conditions: Hallux Valgus and Bunion

Summary: analysis of the collected data to determine: * prevalence. * risk factors. radiological and clinical patterns and their association with specific risk factors of hallux valgus

hallux valgus (hv) is a common foot deformity whose multifactorial and complex and associated with other foot deformities. it is a common 1st ray deformity characterized by excessive angulation, rotation, and lateral deviation of the great toe at the first metatarsophalangeal joint . there are many symptoms of hv include poor fitting shoes, plantar foot pain, and pain in the medial first mtp joint .the resultant deformity causes pain and discomfort, which decreases the physical function of the foot and has been identified as a risk factor for falls in older people . systematic reviews estimated the prevalence of hv to be more frequent with old age and is more prevalent in women . several risk factors for hv have been identified hv is associates with wearing high-heeled or narrow shoes . foot problems are prevalent in old aged and are thought to be associated with high heels and narrow shoes the relationship between hv and obesity is less clear. some studies have found an association between hv and increasing body mass index whereas others have found no association. most recently, it has been suggested that the association between hv and bmi differs between the genders, with a lower prevalence with increasing bmi in women but no association in men and in upper egypt the principle investigator aim to collect data through a cross sectional study to know the prevalence and calculate the percentage of each certain risk factor through ap standing foot and evaluate hv angles and determind who has hv and then calaculate the prevalence and determind associated risk factors , while collecting cases the principle investigator focus on emergency unit on people without foot trauma , no neurological deficit and from outpatient clinic

Eligibility criteria:
inclusion criteria: * aged (18 - 80) including both sexes males and females * patients with no foot trauma or neurological deficit exclusion criteria: 1. post traumatic hallux valgus 2. post infection hallux valgus 3. post surgical hallux valgus -

Keywords: bunion risk factors epidemiology upper egypt
patient-reported outcomes in bladder cancer

Conditions: Bladder Cancer; Urothelial Carcinoma

Summary: electronic reporting of patient-reported outcomes with alert algorithm will be tested in a randomized trial in bladder cancer patients undergoing chemo- or immunotherapy. the clinical endpoints will be: * quality of life * completion of treatment * hospital admission * dose reductions * survival

bladder cancer is in europe the 4th most incident cancer among men and the 7th most frequent cause of cancer death. many patients will receive chemo- or immunotherapy in either the neoadjuvant setting or for recurrent or metastatic disease. the registration and handling of side effect is crucial in bladder cancer treatment, since the missing identification and insufficient treatment of such can lead to incomplete treatment and thereby decreased effect. it is therefore of utmost importance to develop new tools which can increase identification of the side effects and improve treatment to secure the best life expectancies for these patients. this study will in a randomized trial using pro-ctcae™ questions, eortc qlq-c30 + qlq-blm30 in one arm versus standard procedure regarding side effect registration and handling in the other arm, test the effect of electronic reporting of side-effects and quality of life with a specifically developed alert-algorithm. both study arms will include chemotherapy and immunotherapy patients as standard therapy.

Eligibility criteria:
inclusion criteria: * urothelial carcinoma * initiating chemo- or immunotherapy * no serious cognitive deficits * read and understand danish * assigned electronic communication with health services with "e-boks" exclusion criteria: * none

Keywords: patient-reported outcomes electronic reporting of symptoms immunotherapy chemotherapy
covid-19 quantitative antibody titers & booster vaccinations

Conditions: COVID-19; COVID-19 Vaccines; Immunogenicity, Vaccine

Summary: this is an observational study aiming at describing covid-19 vaccination outcomes among hiv-positive and hiv-negative individuals, using electronic health records to observe their usual clinical care. this study will describe levels of covid-19 vaccine response (i.e., ig spike antibody measurements). rates of antibody level decay after vaccination will be assessed. the efficacy of using antibody levels to help guide the timing of booster doses among hiv-negative and hiv-positive patients will be evaluated.

the aim of this study is to assess levels of covid-19 vaccine response through measuring surrogate ig spike antibody measurements, to determine the rates of antibody level decay after vaccination, and to measure the efficacy of utilizing these antibody measurements to help guide the timing of booster doses among hiv-negative and hiv-positive patients. the study population will include adults who were fully vaccinated against sars-cov-2 virus (i.e., two doses of pfizer or moderna vaccines or one dose of the j\&j vaccine), and have received a roche sars-cov-2 semi-quant spike ig ab test at least 3 weeks after full vaccination as part of their usual clinical care at ahf midtown manhattan healthcare center. incidence rates of covid vaccine response levels (i.e., adequate, low, non-response) will be estimated using univariate poisson regression, overall and by vaccine type. among individuals with at least two antibody measurements, rates of antibody levels decay will be estimated using univariate linear regression, overall and stratified by hiv status, vaccine type and baseline cd4 cell count. in the sub-population of individuals who received a covid vaccine booster, vaccination and antibody response will be characterized at least 3 weeks after the booster is received. univariate linear regression will be used to estimate rates of antibody levels decay, among individuals with at least two antibody measurements, including one after the booster dose. rates of response decay will be produced overall, and stratified by hiv status, booster type and baseline cd4 cell count.

Eligibility criteria:
inclusion criteria: * cared for at ahf midtown manhattan healthcare center and followed in the opera observational database * active in care in the last 24 months * fully vaccinated against sars-cov-2 virus, implemented as 21 days after the second pfizer or moderna injections, 21 days after the one j\&j injection * received a roche sars-cov-2 semi-quant spike ig ab test after full vaccination as usual clinical care exclusion criteria: * unvaccinated or partially vaccinated against sars-cov-2 virus * never tested with a sars-cov-2 semi-quant total ab test after full vaccination

Keywords: covid-19 observational vaccination antibody booster
neurogenic intermittent claudication evaluation study

Conditions: Spinal Stenosis

Summary: the objective of the nice study is to provide clinical evidence proving that the aperius™ perclid™ system is safe and non-inferior to standalone decompressive surgery with regards to clinical outcomes in patients suffering from degenerative lumbar spinal stenosis with neurogenic intermittent claudication, relieved by flexion.

the nice study is a multicenter prospective randomized controlled clinical trial to evaluate the effectiveness and safety of the aperius™ perclid™system versus standalone decompressive surgery in degenerative lumbar spinal stenosis with neurogenic intermittent claudication. dlss patients suffering from nic that would be candidates for surgical treatment without stabilization and/or fusion can be offered participation in the study. after randomization, patients will be treated with either the aperius™ perclid™ system or standalone decompressive surgery (sds). a sample size recalculation reduced the amount of patients to be enrolled from 280 to 128 in both treatment group. the patient will undergo a study visit at screening / baseline and at 14 days, 6 weeks, 6, 12 and 24 months after surgery. safety data will be collected during surgery and throughout the 24 months follow up. procedural details will be collected during surgery and also duration of hospital stay will be collected. at screening / baseline and all follow up visits a physical examination will be performed, the use of pain medication will be documented and the subject will be asked to complete a pain vas scale (back - leg - buttock / groin pain) and questionnaires (sf36 v2 and zurich claudication questionnaire). study subjects are required to undergo x-ray, ct and mri and fluoroscopy procedures at specified time points during the study.

Eligibility criteria:
inclusion criteria: * presence of symptomatic dlss * presence of nic * patient would be candidate for standalone decompressive surgery * patient has signed informed consent form (icf) * patient is 21 years old or older exclusion criteria: * previous lumbar surgery * patient is candidate for instrumented decompressive surgery * patient has back pain without leg pain * degenerative spondylolisthesis greater than grade 1 (meyerding) * symptomatic dlss at more than 2 levels in the lumbar region * spinal stenosis is present at l5-s1 level